NCT06978322

Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Minia University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial aimed to determine whether neoadjuvant chemoradiotherapy improves overall survival compared with upfront surgery, both followed by adjuvant chemotherapy in patients with resectable and borderline resectable pancreatic cancer.

Detailed description

Pancreatic cancer is one of the solid cancers with the poorest treatment outcomes, and there is an urgent need to improve its treatment outcomes. Among these, resectable pancreatic cancer is known to show relatively good treatment outcomes with surgical resection, but the 5-year survival rate is still about 20%, which is still unsatisfactory. Neoadjuvant therapy may increase the proportion of patients that actually receive chemotherapy and thereby improve survival. Furthermore, neoadjuvant therapy may increase the microscopically margin-negative (R0) resection rate and may identify patients with rapidly progressive disease who can be spared futile surgery.

Conditions

• Surgery
• Neoadjuvant Chemotherapy
• Management
• Resectable Pancreatic Cancer

Interventions

Type	Name	Description
PROCEDURE	Immediate surgery	Patients will undergo upfront surgery, then adjuvant chemotherapy.
PROCEDURE	Neoadjuvant chemotherapy	Patients will undergo neoadjuvant chemotherapy, then surgery.

Timeline

• Start date: 2025-02-01
• Primary completion: 2026-02-01
• Completion: 2026-02-01
• First posted: 2025-05-18
• Last updated: 2025-05-18

Locations

1 site across 1 country: Egypt